Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HBM HOLDINGS-B Enters Strategic Co-op with Bristol Myers Squibb, May Receive Max. US$1.035B in Milestone Payments/ Royalties
Recommend 5 Positive 6 Negative 5 |
||||
|
||||
|
HBM HOLDINGS-B (02142.HK) and Bristol Myers Squibb have entered into a multi-year, global strategic collaboration and license agreement, which aims to discover and develop next-generation multi-specific antibodies, as announced by HBM HOLDINGS-B. Under the terms of the agreement, in return, HBM HOLDINGS-B could receive payments totaling US$90 million as well as development, and commercial milestones of up to US$1.035 billion, along with tiered royalties should Bristol Myers Squibb elect to advance all potential programs. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
